Mutations in the RHO gene are the main cause of dominant forms of retinitis pigmentosa (RP). RHO dictates the production of rhodopsin, a transmembrane protein present in large quantities in the outer ...
Read moreResearchers from the Seoul National University (Korea) have applied for the first an improved genome-editing methodology, named prime editing to correct the genetic defects of two animal models of hum...
Read moreEditas Medicine, a company specialising in the development of gene editing therapies, has announced the recruitment of paediatric patients to the Brilliance trial.
Read moreThe SJD-Hospital Bellvitge Hereditary Retinal Dystrophy Unit has applied Novartis' Luxturna therapy to Noa, who only retained 3% of her vision.
Read moreAs chemical and life science companies seeking to monetize their IP portfolios emerge from the challenges of COVID-19, 2021 looks to be a year that will see increased product licensing, acquisitions a...
Read moreThe life science company Sartorius signed a strategic collaboration with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media a...
Read morePatients with severe COVID-19 disease have significantly shorter telomeres, according to a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) in collaboration with th...
Read moreAsphalion’s Board of Directors is pleased to announce the appointment of Christopher Mann as new Scientific and Regulatory Affairs Director.
Read moreThe life science company Sartorius today acquired U.S.‑based purification expert WaterSep BioSeparations LLC through its subgroup Sartorius Stedim Biotech.
Read moreSara Secall, a chemistry graduate with a master’s degree in environmental science and an MBA, is the current partner and director of investments in Life Sciences at Inveready, a Venture Capital (VC)...
Read moreMacular degeneration, Age-related macular degeneration, Gene Therapy
Read moreHospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating hematological malignancies. The company raised
Read more